What is Novo Nordisk AS Price-to-Operating-Cash-Flow?
As of today (2025-06-04), Novo Nordisk AS's share price is kr466.675.
Novo Nordisk AS's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was kr29.44. Hence, Novo Nordisk AS's Price-to-Operating-Cash-Flow Ratio for today is 15.85.
The historical rank and industry rank for Novo Nordisk AS's Price-to-Operating-Cash-Flow or its related term are showing as below:
CHIX:NOVOBc'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.41 Med: 21.69 Max: 48.32
Current: 15.84
During the past 13 years, Novo Nordisk AS's highest Price-to-Operating-Cash-Flow Ratio was 48.32. The lowest was 11.41. And the median was 21.69.
Novo Nordisk AS's Cash Flow from Operations per share for the
three
months ended in Mar. 2025 was kr5.53.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was kr29.44.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Novo Nordisk AS was 41.40% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 31.40% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 24.90% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 14.60% per year.
During the past 13 years, Novo Nordisk AS's highest 3-Year average Operating Cash Flow per Share Growth Rate was 136.20% per year. The lowest was -46.40% per year. And the median was 16.80% per year.
Novo Nordisk AS Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Novo Nordisk AS's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS Price-to-Operating-Cash-Flow Chart
|
Novo Nordisk AS Annual Data
|
|
Trend |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
Dec24 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
19.22 |
30.78 |
27.02 |
28.81 |
23.03 |
|
Novo Nordisk AS Quarterly Data
|
|
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
Jun24 |
Sep24 |
Dec24 |
Mar25 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
42.35 |
39.02 |
29.72 |
23.03 |
15.96 |
Competitive Comparison of Novo Nordisk AS's Price-to-Operating-Cash-Flow
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Price-to-Operating-Cash-Flow falls into.
Novo Nordisk AS Price-to-Operating-Cash-Flow Calculation
Novo Nordisk AS's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 466.675 | / | 29.435 |
| = | 15.85 |
Novo Nordisk AS's Share Price of today is kr466.675.
Novo Nordisk AS's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr29.44.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Novo Nordisk AS Business Description
Traded in Other Exchanges
Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Novo Nordisk AS Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHIX:NOVOBC has been successfully added to your